Evidence map›Paper›PMID 29545597›Full record

ArticleScientific reports2018

Rare variants in drug target genes contributing to complex diseases, phenome-wide.

Shefali Setia Verma, Navya Josyula, Anurag Verma, Xinyuan Zhang, Yogasudha Veturi, Frederick E Dewey, Dustin N Hartzel, Daniel R Lavage, Joe Leader, Marylyn D Ritchie and 1 more

Erratum issuedAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Genetic Analysis of Functional Rare Germline Variants across Nine Cancer Types from an Electronic Health Record Linked Biobank.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Shefali Setia VermaPerelman School of Medicine, Department of Genetics, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Navya JosyulaBiomedical and Translational Informatics Institute, Geisinger, Danville, PA, 17221, USA.ORCID 0000-0003-2782-8812
Anurag VermaPerelman School of Medicine, Department of Genetics, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Xinyuan ZhangPerelman School of Medicine, Department of Genetics, University of Pennsylvania, Philadelphia, PA, 19104, USA.ORCID 0000-0002-8885-1146
Yogasudha VeturiPerelman School of Medicine, Department of Genetics, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Frederick E DeweyRegeneron Genetics Center, Tarrytown, NY, 10591, USA.
Dustin N HartzelPhenomic Analytics and Clinical Data Core, Geisinger, Danville, PA, USA.
Daniel R LavagePhenomic Analytics and Clinical Data Core, Geisinger, Danville, PA, USA.
Joe LeaderBiomedical and Translational Informatics Institute, Geisinger, Danville, PA, 17221, USA.
Marylyn D RitchiePerelman School of Medicine, Department of Genetics, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Sarah A PendergrassBiomedical and Translational Informatics Institute, Geisinger, Danville, PA, 17221, USA. spendergrass@geisinger.edu.

Funding

OMOP information model for eMERGE phenotypingU01HG008679 · NHGRI · GEISINGER CLINIC · PI WILLIAMS, MARC S. · 2015 to 2019
$4.4M
NHGRI NIH HHS U01 HG008679
6 · The paper itself

Abstract

The DrugBank database consists of ~800 genes that are well characterized drug targets. This list of genes is a useful resource for association testing. For example, loss of function (LOF) genetic variation has the potential to mimic the effect of drugs, and high impact variation in these genes can impact downstream traits. Identifying novel associations between genetic variation in these genes and a range of diseases can also uncover new uses for the drugs that target these genes. Phenome Wide Association Studies (PheWAS) have been successful in identifying genetic associations across hundreds of thousands of diseases. We have conducted a novel gene based PheWAS to test the effect of rare variants in DrugBank genes, evaluating associations between these genes and more than 500 quantitative and dichotomous phenotypes. We used whole exome sequencing data from 38,568 samples in Geisinger MyCode Community Health Initiative. We evaluated the results of this study when binning rare variants using various filters based on potential functional impact. We identified multiple novel associations, and the majority of the significant associations were driven by functionally annotated variation. Overall, this study provides a sweeping exploration of rare variant associations within functionally relevant genes across a wide range of diagnoses.

Indexed as

Databases, PharmaceuticalPhenotypePolymorphism, Single NucleotideAlgorithmsBiomarkersComputational BiologyDiseaseGenetic Association StudiesGenome, HumanGenome-Wide Association StudyGenotypeHumansPharmaceutical PreparationsBiomarkersPharmaceutical Preparations

Identifiers

PMID29545597
PMCPMC5854600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.